203 related articles for article (PubMed ID: 17020450)
1. Role of fludarabine in hematological malignancies.
Montillo M; Ricci F; Tedeschi A
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1141-61. PubMed ID: 17020450
[TBL] [Abstract][Full Text] [Related]
2. Cellular and clinical pharmacology of fludarabine.
Gandhi V; Plunkett W
Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
[TBL] [Abstract][Full Text] [Related]
3. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with fludarabine in hemato-oncology.
Keating MJ; O'Brien S; McLaughlin P; Dimopoulos M; Gandhi V; Plunkett W; Lerner S; Kantarjian H; Estey E
Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S83-91. PubMed ID: 9137961
[TBL] [Abstract][Full Text] [Related]
5. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review).
Van den Neste E; Cardoen S; Offner F; Bontemps F
Int J Oncol; 2005 Oct; 27(4):1113-24. PubMed ID: 16142330
[TBL] [Abstract][Full Text] [Related]
6. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes.
Sandoval A; Consoli U; Plunkett W
Clin Cancer Res; 1996 Oct; 2(10):1731-41. PubMed ID: 9816124
[TBL] [Abstract][Full Text] [Related]
8. Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.
McCune JS; Mager DE; Bemer MJ; Sandmaier BM; Storer BE; Heimfeld S
Cancer Chemother Pharmacol; 2015 Jul; 76(1):85-96. PubMed ID: 25983023
[TBL] [Abstract][Full Text] [Related]
9. Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism.
Huang P; Plunkett W
Mol Pharmacol; 1991 Apr; 39(4):449-55. PubMed ID: 1708088
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro.
Li L; Liu X; Glassman AB; Keating MJ; Stros M; Plunkett W; Yang LY
Cancer Res; 1997 Apr; 57(8):1487-94. PubMed ID: 9108450
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences.
Gandhi V; Huang P; Chapman AJ; Chen F; Plunkett W
Clin Cancer Res; 1997 Aug; 3(8):1347-55. PubMed ID: 9815818
[TBL] [Abstract][Full Text] [Related]
12. [A new purine analog in the treatment of hematologic malignancy. I. Fludarabine].
Vásová I; Penka M; Hájek R; Mayer J; Krahulcová E
Vnitr Lek; 1997 Jan; 43(1):45-50. PubMed ID: 9221567
[TBL] [Abstract][Full Text] [Related]
13. F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.
Bonin M; Pursche S; Bergeman T; Leopold T; Illmer T; Ehninger G; Schleyer E; Bornhauser M
Bone Marrow Transplant; 2007 Feb; 39(4):201-6. PubMed ID: 17211431
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of purine nucleoside analogues.
Plunkett W; Gandhi V
Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S67-74. PubMed ID: 9137959
[TBL] [Abstract][Full Text] [Related]
15. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Leuk Lymphoma; 1993 May; 10(1-2):49-56. PubMed ID: 8374523
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and action of fludarabine phosphate.
Plunkett W; Huang P; Gandhi V
Semin Oncol; 1990 Oct; 17(5 Suppl 8):3-17. PubMed ID: 1699280
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388.
Avramis VI; Plunkett W
Cancer Res; 1982 Jul; 42(7):2587-91. PubMed ID: 7083151
[TBL] [Abstract][Full Text] [Related]
18. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
Kemena A; Gandhi V; Shewach DS; Keating M; Plunkett W
Cancer Chemother Pharmacol; 1992; 31(3):193-9. PubMed ID: 1464155
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of nelarabine in indolent leukemias.
Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
